Janux Therapeutics, Inc. is an innovative biopharmaceutical company based in La Jolla, California, specializing in the development of advanced immunotherapies for cancer treatment through its proprietary Tumor Activated T Cell Engager (TRACTr) platform. The company aims to enhance patient outcomes by creating therapies that specifically target and eliminate tumor cells, addressing critical unmet needs in oncology. With a strong emphasis on T cell biology and tumor activation mechanisms, Janux is poised to make significant contributions to cancer care, driven by its cutting-edge research and strategic focus on innovative therapeutic solutions.